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Abstract 
BACKGROUND: Medication non-adherence is associated with poor health outcomes and increased healthcare 
costs. Although the use of tyrosine kinase inhibitor (TKI) for chronic myeloid leukemia (CML) treatment is 
satisfactory in clinical results, it is subject to non-adherence. In this study, we intend to verify if there are 
psychological factors, such as anxiety, depression, and coping style that can influence medication adherence. 
METHODS: The study was conducted on 120 patients with CML receiving long-term TKI therapy. The sample was 
collected in the years 2016-2017 at Department of Oncology-Hematology in Pescara, Italy. Adherence behaviour 
was measured with the eight-item Morisky Medication Adherence Scale (MMAS-8) and psychological factors 
investigated included: anxiety and depression symptoms [Hospital Anxiety and Depression Scale (HADS)] and 
coping strategies [abbreviated version of the Coping Orientation to Problems Experienced (Brief-COPE)]. T-test and 
logistic regression analyses were performed to investigate factors associated with medication adherence. 
RESULTS: The participants, 74 men and 46 women, reported a mean age of 56.65 ± 15.80 years. The results 
showed that 71.67% of the patients were adherent while 28.33% were non-adherent. Furthermore, adherence was 
positively associated with active coping (P < 0.050) and instrumental support (P < 0.001). Also, depression 
symptoms were risk factor for non-adherence (P < 0.050). 
CONCLUSION: This study suggests that active coping strategies with a good level of instrumental support are 
factors associated with greater adherence to long-term therapy. The results of this study support paying attention 
to factors identified as being helpful in monitoring patients with a risk of non-adherence. There is a need to provide 
increased psychosocial support for patients with chronic disease by planning effective client‐focused interventions. 
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Introduction1 
The use of the new tyrosine kinase inhibitor 
(TKI) has revolutionized the treatment of chronic 
myeloid leukemia (CML). Since the advent of 
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TKI, patients with CML had significantly 
improved prognosis. Although most patients 
treated with TKI have durable responses, 
resistance and side effects occur in some patients. 
This induces the patient to postpone or refuse 
the treatment. This is the reason why today there 
is a great difficulty in achieving an adequate 
therapeutic compliance.1 According to the World 
Health Organization (WHO), approximately 
50% of chronically ill patients who undergo 
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medication and non-adherence is related with 
poor health outcomes and increased healthcare 
costs.2 A systematic review about adherence in 
patients with hematological malignancies reports 
adherence rates between 20%-53% in patients 
with CML and non-adherence rates of 6%-35% in 
patients with acute lymphoid leukemia (ALL).3 
In addition, socio-economic factors are found to 
be associated to medication non-adherence.4,5 A 
recent study shows how in patients with CML 
treated with imatinib (IM) for some years, poor 
adherence may be the predominant reason for 
inability to obtain adequate molecular responses. 
In addition, optimal drug adherence was 
associated with positive health outcomes.6 
Another study shows that the higher the 
adherence, the lower the level of breakpoint 
cluster region gene (BCR) at chromosome 22q11 
to the Abelson gene (ABL1) (BCR-ABL1), but 
there are not many studies that investigate the 
influence of psychological factors on adherence.7 
Coping strategies influence non-adherence 
and comorbidities in patients with chronic 
disease.8 Exploration of these influencers has 
important implications for health education. 
Coping refers to the way an individual engages, 
both behaviourally and cognitively, to attenuate 
the impact of a stressor.9 Coping is most 
commonly divided into two patterns: active (or 
problem-focused) and passive (or emotion-
focused). Preceding studies have shown that 
people who respond with acceptance, positive 
reinterpretation, and problem-focused coping 
appear to be correlated to better psychological 
condition and better illness outcome, whereas a 
passive coping style is correlated with worse 
illness outcome.10 
Other psychological factors associated with 
poor adherence are depressive and anxiety 
symptoms. A recent study shows the depressive 
trait as independent predictor of medication 
adherence.11 Also, the results indicate that 
patients with psychological distress are at 
increased risk of non-adherence, and could 
therefore benefit from extra attention from the 
healthcare professionals. Patients with 
symptoms of anxiety and/or depression should 
be identified and monitored in order to improve 
adherence to medication regimens. The 
assessment of anxiety and depression in patients 
with acute leukemia since hospital admission is 
substantial for the adherence to treatment.12 
Therefore, this cross-sectional study looked 
at patients with CML hospitalized in the 
Department of Oncology-Hematology, UOC 
Clinical Hematology, Regional Authority of 
Abruzzo, Pescara, Italy. The hypothesis is that 
non-adherent patients manifested more 
depression and anxiety symptoms compared 
to adherent patients, and that some coping 
strategies can be predictors of a good 
adherence. Therefore, the aim of this study is 
to determine the relationship of coping styles, 
anxiety, and depression with adherence in 
patients with TKIs treatment. 
Materials and Methods 
The study was submitted and approved by the 
Ethical Committee with the name of 
“Observational study of psychological factors: 
Adherence in treatment with TKI in CML”. The 
research protocol was also authorized by the 
Ethics Committee (code: LMC-QoL01 of 
28/09/2015) of ASL of the General Hospital in 
Pescara. The research was conducted with 
respect for the rights of all participants and the 
data were analysed entirely anonymously. Thus, 
all 120 participants were volunteers who filled 
out the questionnaires in a confidential setting. 
A consecutive and unselected sample of 122 
patients in the Department of Oncology-
Hematology of the Civil Hospital, in Pescara was 
recruited in the years 2016-2017. Of the 122 
recruited patients, 120 (98.3%) accepted to be 
enrolled. There are no missing data. Therefore, 
the sample consisted of 120 patients of both 
genders with a medically-documented diagnosis 
of CML, in the first line of treatment with TKIs, 
according to the diagnostic criteria of the WHO. 
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hospitalized in the UOC Clinical Hematology 
and all patients were contacted by clinical 
psychologists in collaboration with medical 
hematologists. We included patients of both 
sexes who met the following inclusion criteria: a) 
adult patients with an age ranging from 18 to 75 
years, b) diagnosis of CML, and c) patients in 
treatment with TKI for at least six months. By 
contrast, patients with severe addictions and 
neurological or psychiatric disorders were 
excluded from the study. Moreover, patients 
suffering from CML previously submitted to 
bone marrow transplantation (BMT) and 
patients with CML who had undergone TKI for 
less than 6 months were excluded from the 
study. All participants completed the following 
self-rating scales: Hospital Anxiety and 
Depression Scale (HADS), abbreviated version of 
the Coping Orientation to Problems Experienced 
(Brief-COPE), and eight-item Morisky 
Medication Adherence Scale (MMAS-8). 
The demographic and social factors such as 
age, gender, and housing situation were collected 
at baseline (i.e., at the time of diagnosis) (Patient 
Advocacy and Research Ethics). The clinical 
outcomes including the years of therapy, monitor, 
report, respond, and remedy ate (MR3), anxiety, 
and depression were obtained from the patients’ 
medical records. 
The presence of depressive and anxiety 
symptoms was assessed using clinical 
interview and self-report HADS.13 HADS scale 
was used to measure anxiety and depression 
levels and consisted of two subscales. Both of 
them were structured of seven items scored 
from 0 to 3. Out of a possible 21 points, 0-7 
points were considered normal, scores ranging 
between 8 to 10 were considered borderline, 
and > 11 points indicate severe symptoms of 
anxiety and depression. 
The MMAS-8,14 a standardised test, was 
used to measure adherence. Patients who 
scored 8 points, < 8 to > 6 points, and ≤ 6 
points on the scale were considered to have 
high, medium, and low adherence, 
respectively. This test has been developed 
from the well-validated Morisky-Green Test 
and The eight-item Morisky Medication 
Adherence Scale (MMAS-8). The internal 
consistency reliability of the Italian version of 
8-item MMAS, measured by the Crohnbach’s 
α, had a value of 0.89. The MMAS is composed 
of 8 questions that explore adherence 
behaviour based on forgetfulness, negligence, 
interruption of drug intake, and restart when 
symptoms worsen. This definition of 
adherence is based on how patients 
theoretically would have completed the 
MMAS if they had taken at least 95% of 
prescribed doses. 
The Brief-COPE15 is a self-report, validated, 
28-item questionnaire that evaluates state 
coping, which is the manner in which an 
individual copes in response to a specific 
situation (i.e., the cancer diagnosis). It consist of 
14 subscales (2 items per subscale) measuring 
the following: self-distraction, active coping, 
denial, substance use, use of emotional support, 
use of instrumental support, behavioural 
disengagement, venting, positive reframing, 
planning, humour, acceptance, religion, and 
self-blame. Cronbach’s α ranges from 0.50 to 
0.90 for the Brief-COPE subscales. Each single 
item is scored along a 4-point scale with the 
following options: 1) I usually do not do this at 
all, 2) I usually do this a little bit, 3) I usually do 
this a medium amount, and 4) I usually do this 
a lot. The following 8 subscales are classified as 
adaptive strategies: active coping, planning, 
positive re-framing, acceptance, humour, 
religion, use of emotional support, and use of 
instrumental support. The remaining 6 subscales 
are considered to be maladaptive and include 
self-distraction, denial, venting, substance use, 
behavioural disengagement, and self-blame. The 
maximum score for the 14 subscales is 8 points, 
with a higher score indicating greater use of a 
specific coping strategy.  
A 3-step strategy was used for data analysis. 
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between adherent and non-adherent patients 
were compared using Student’s t-test or chi-
square test, and effect sizes were expressed as 
standardized mean differences. A standardized 
effect size (Cohen’s d) of 0.20-0.50 is considered 
small, 0.50-0.80 moderate, and > 0.80 is 
considered large. The reliability of the applied 
scales was assessed using Cronbach’s α 
coefficient. Second, binary logistic regression 
analysis was performed to identify major 
determinants that best predict the adherence; 
the letter as a dependent variable (dummy 
coded: 0 = low adherence, 1 = adherence) and 
the independent variables were age, sex, years 
of therapy, depression, and anxiety symptoms 
and coping strategies. Four regression models 
were processed and regression coefficients, the 
related confidence intervals (CIs), odds ratios 
(ORs), and P-values were estimated. We also 
calculated the R² coefficient value for each of 
the adjusted models. Third, direct maximum 
likelihood (ML) confirmatory factor analysis 
(CFA) was used to examine the construct 
validity of the Italian MMAS-8 scale. Data were 
analysed using Stata software (version 13, Stata 
Corporation, College Station, TX, USA) at the 
statistical significance level of P < 0.050. 
Results 
120 participants reported a mean age of 56.65 ± 
15.80 years, with ages between 23 and 75 years 
and were predominantly men (n = 74). Most of 
the participants resulted to be currently married 
(n = 104) and the participants of the study were 
assessed for years of therapy that showed an 
average of 6.30 [standard deviation (SD) = 4.6] 
years. Table 1 reports the comparisons between 
adherent and non-adherent patients. According 
to our results, 71.67% of patients were 
considered as adherers; therefore, they 
regularly followed the recommended drug 
therapy, while 28.33% of the patients presented 
non-adherence to the drug therapy. To check 
the reliability of the factors (psychological 
dimensions), Cronbach’s α coefficients were 
computed. The results showed that Cronbach’s 
α resulted greater than 0.70 for all the factors, 
meaning that each factor scale had consistency. 
No between-group significant differences were 
found in socio-demographic and clinical (years 
of therapy) characteristics. The two subgroups 
of patients, adherent and non-adherent, were 
markedly different when they were evaluated 
for active coping, emotional and instrumental 
support, with low effect sizes in the small 
range. Adherent patients reported significantly 
higher active coping and emotional and 
instrumental support scores than non-adherent 
patients (5.64 ± 1.73 vs. 5.27 ± 1.94, 4.40 ± 1.88 
vs. 3.97 ± 1.74, 4.97 ± 1.97 vs. 4.27 ± 1.97, 
respectively) with effect size of d = 20, d = 23, 
and d = 35, respectively. Same significant 
between-group differences were found for the 
depression symptoms but not the anxiety trait. 
Moreover, non-adherent patients had 
significantly higher depressive (9.63 ± 6.03) 
scores than the adherent group (5.31 ± 4.56)  
(d = 0.32). A significant difference was found 
between groups for MR3 clinical variable  
(P < 0.001) (Table 1). 
4 regression models with adherence score as 
binary outcome were explained. The first model 
with age and sex, as principal predictors, 
explained a small part of the adherence variance 
(R2 = 0.04). The second model was adjusted with 
years of therapy and MR3 variables adding 17% 
to the explained variance (OR = 1.03). The third 
model adjusted for depressive and anxiety scale 
explained a major part of the variance (R2 = 0.19). 
The final model, adjusted for emotional support, 
active coping, and instrumental support scores 
predicted 22% of the explained variance  
(OR = 0.95, OR = 1.02, OR = 1.32, respectively). 
The results showed that depression symptoms  
(P ≤ 0.050) were risk factors of non-adherence, 
but active coping (P ≤ 0.050) and instrumental 
support (P ≤ 0.001) were significant predictors of 
adherence. No significant results were found for 
age, gender, years of therapy, anxiety symptoms, 
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Table 1. Socio-demographic and clinical characteristics of the study sample: Comparison with 
adherence (n = 120) 
Variable  Total sample 
(n = 120) 
Adherence  
(n = 86) 
Non-Adherence  
(n = 34) 
t/χ
2
 P  Cohen’s d 
Gender Men 74 52 (60.47) 22 (64.71) -0.42 0.670 0.08 
Women 46 34 (39.53) 12 (35.29) 
Housing 
situation 
Living alone 16 12 (13.95) 4 (11.77) 0.31 0.750 0.18 
Living with others 104 74 (86.05) 30 (88.23) 
MR3 Yes 107 84 (97.67) 23 (67.64) 5.25 < 0.001 0.80 
No 13 2 (2.33) 11 (32.36)   
Age (year)   56.65 ± 15.80 57.49 ± 15.42 54.61 ± 16.98 -0.88 0.370 0.18 
Brief-COPE Active coping 5.38 ± 1.88 5.64 ± 1.73  5.27 ± 1.94 1.96 < 0.001 0.20 
Planning 5.45 ± 2.10 5.47 ± 2.17 5.38 ± 1.93 -0.22 0.820 0.04 
Positive refraining 5.63 ± 1.99 5.60 ± 2.11 5.70 ± 1.67 0.24 0.800 0.05 
Acceptance 7.15 ± 1.40 7.17 ± 1.48 7.08 ± 1.21 -0.30 0.760 0.06 
Humour 3.92 ± 1.76 7.89 ± 1.77 4.00 ± 1.75 0.29 0.750 0.05 
Religion 5.15 ± 2.26 5.24 ± 2.26 4.94 ± 2.29 -0.66 0.500 0.13 
Emotional support 4.28 ± 1.85 4.40 ± 1.88 3.97 ± 1.74 1.16 < 0.001 0.23 
Instrument support 4.78 ± 1.99 4.97 ± 1.97 4.27 ± 1.97 -1.74 < 0.001 0.35 
Self-distraction 5.00 ± 1.98 5.10 ± 2.02 4.76 ± 1.89 -0.84 0.400 0.17 
Denial 2.90 ± 1.66 2.93 ± 1.74 2.85 ± 1.45 0.22 0.810 0.04 
Venting 4.11 ± 1.86 4.77 ± 1.89 3.73 ± 1.78 -1.42 0.100 0.28 
Substance use 2.12 ± 0.64 2.16 ± 0.74 2.03 ± 0.17 -1.01 0.310 0.20 
Behavioural 
disengagement 
3.11 ± 1.68 3.19 ± 1.67 2.91 ± 1.71 -0.83 0.400 0.16 
Self-blame 3.88 ± 1.49 3.86 ± 1.59 3.96 ± 1.21 0.32 0.740 0.07 
Years of 
therapy 
 6.30 ± 4.64 6.46 ± 4.67 5.86 ± 2.01 0.59 0.550 0.12 
HADS-D   6.56 ± 5.26 5.31 ± 4.56 9.63 ± 6.03 -5.21 < 0.001 0.32 
HADS-A   6.61 ± 3.80 6.45 ± 3.84 7.02 ± 3.74 0.74 0.450 0.15 
Data are presented as mean ± standard deviation (SD) or number and percentage 
MR3: monitor, report, respond, and remediate; COPE: Coping Orientation to Problems Experienced; HADS-A: Hospital Anxiety and 
Depression Scale-Anxiety subscale; HADS-D: Hospital Anxiety and Depression Scale-Depression subscale 
 
 
At last, the CFA showed satisfactory 
construct and results pointed to a one-factor 
solution in all the items contributed to the final 
index of adherence. Accordingly, the Italian 
version of the MMAS-8 is a reliable and valid 
measure of medication adherence (Table 3). 
 
Table 2. Predictors of adherence, results of binary regression models (n = 120) 
Variables β OR (95% CI) P R
2
 
Model 1    0.04 
Age 0.01 1.01 (0.98-1.03) 0.950 
Gender 0.28 0.64 (0.28-1.46) 0.290 
Model 2    0.17 
+ Years of therapy 0.03 1.03 (0.93-1.13) 0.640 
+ MR3 0.73 1.11 (0.95-1.19) < 0.001 
Model 3    0.19 
+ HADS-A 0.05 0.95 (0.83-1.11) 0.440 
+ HADS-D -0.11 1.02 (0.85-1.13) < 0.050 
Model 4    0.22 
+ Emotional support 0.04 0.95 (0.78-1.35) 0.790 
+ Active coping 0.15 1.02 (1.05-1.09) < 0.050 
+ Instrumental support 0.30 1.32 (0.94-1.85) < 0.001 
HADS-A: Hospital Anxiety and Depression Scale-Anxiety subscale; HADS-D: Hospital Anxiety and 





http://cdjournal.muk.ac.ir,    05 July 
Tyrosine kinase inhibitor in CML Francesco et al. 
  136   Chron Dis J, Vol. 8, No. 3, Summer 2020 
Table 3. Factor loading patterns of the Italian eight-item Morisky Medication Adherence Scale  
(MMAS-8) (n = 120) 
Item as numbered in the original MMAS-8 Items loading 
1. Do you sometimes forget to take your medications? 0.61 
2. People sometimes miss taking their medications for reasons other than forgetting. Thinking over 
the past two weeks, were there any days when you did not take your medicine? 
0.73 
3. Have you ever cut back or stopped taking your medication without telling your doctor, because 
you felt worse when you took it? 
0.44 
4. When you travel or leave home, do you sometimes forget to bring along your medication? 0.59 
5. Did you take your medicine yesterday? 0.32 
6. When you feel like you are under control, do you sometimes stop taking your medicine? 0.62 
7. Taking medication every day is a real inconvenience for some people. Do you ever feel hassled 
about sticking to your treatment plan? 
0.40 
8. How often do you have difficulty remembering to take all your medications? 0.28 
Values in bold are those with a loading at 0.32 or higher on a factor which means that they pertain to this factor 
MMAS-8: Eight-item Morisky Medication Adherence Scale 
 
Discussion 
Patients with chronic disease could have 
different elapses and evolutions, not always 
explainable with organic factors or with 
objective differences of environmental or social 
contexts. The way in which the patient can 
give a meaning to the drug, which is both 
slavation (Patient Advocacy and Research 
Ethics) and limit, will have great importance 
for the whole run of his/her own illness. In 
psychology, adherence is a process by which 
individuals create their own balance or at least, 
an absence of conflict, with the environmental 
conditions. The adherence of patients with 
chronic illness is a mediator among the 
psychological, social, environmental, and 
physical characteristics that plays a crucial 
role. A complete adherence is the moment 
when the patient is included in his/her life 
medicine and the disease.16 
Given the paucity of data in the CML 
literature, we selected possible factors 
associated with adherence behaviour based on 
previous studies in other chronic medical 
conditions. Evidence from other studies on 
adherence in chronic patient populations 
showed that younger age was associated with 
lower adherence as well.17 
There are a number of studies which 
focused on anxiety and depression in cancer; 
however, the same interest is not observed in 
the field of hematologic malignancies. This 
study was to test the prevalence of adherence 
to TKI treatment in patients with CML and 
evaluate psychological factors (anxiety and 
depression traits) associated with adherence. 
The second step was to explore the association 
between coping styles as predictors of 
adherence. The results confirm that patients 
with a good level of adherence are 71.67% of 
the observed group. Furthermore, the results 
confirm that in CML therapy, a good 
adherence is essential for a successful 
treatment. However, this element decreases 
with the increase of the years of treatment for 
both sexes, but in our study, it is not 
statistically significant. 
Psychological and medical supports at the 
time of diagnosis and during treatment are 
essential to revitalize the patient’s desire to live 
and increase the adherence to treatment.12 The 
study of psychological dimensions in patients 
with CML showed that some coping strategies 
were potentially significant for the definition 
of adherence. A recent study by Conti et al. 
shows that increasing the depression levels 
decreases the medication adherence;18 and also 
from our results, it is observed that depression 
is a risk factor for low adherence. 
As for the coping behaviour, it has been 
shown that the use of the active coping 
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controlling) helps patients with cancer to 
significantly reduce the level of anxiety and 
depression caused by the uncontrollable threat 
to life and the high uncertainty of the disease 
situation. It has been indicated that excessive 
use of an avoidance coping style can easily 
produce negative emotions and then affect 
treatment adherence.19 The use of passive 
emotional-oriented coping strategies such as 
avoidance is often associated with low 
adherence to treatment in patients with 
chronic disease. In a recent study, even a 
negative effect of the avoiding coping on 
outcome of cancer was found.20 As well, in this 
study, we found a positive relationship 
between adherence and patient’s coping 
strategies; patients showing greater adherence 
frequently use coping strategy as: active 
coping and instrumental support. Binary 
regression analysis reflected the need for 
developing strategies to strengthen 
instrumental support and active coping as a 
factor in promoting adherence to treatment, 
but it shows that patients with high levels of 
depression have low adherence to therapy. 
Therefore, depression symptoms can be risk 
factors for health outcomes. 
This study contributes to the growing 
literature on the effect of depression symptoms 
and coping style on adherence. Our results 
imply that interventions that improve coping 
style and better adherence may lead to 
improved health outcomes and should thus be 
explored. Hence, to prevent negative emotions 
and treatment non-adherence in the future, 
psychological interventions should be 
conducted to improve the coping style of 
haematological patients. We can say that 
psychological support improves adherence. 
Another limitation of the study was that 
due to its cross-sectional nature, it only 
explains the relationship between the variables 
affecting adherence and is not capable of 
showing the sequence. Longitudinal studies 
could provide more insight into the 
underlying mechanism of the relationships 
found in this study. 
Conclusion 
Patients with symptoms of anxiety and/or 
depression should be identified and monitored 
in order to improve adherence to medication 
regimens. In conclusion, the regression models 
explained less than 22% of the variance of the 
study outcome. Therefore, further research is 
required to explore which additional factors 
can determine coping styles and adherence 
among patients with CML. 
Limitations: This study is not without 
limitations. First, because it was conducted in a 
relatively small group of inpatients treated in a 
single health facility, its results are applicable 
only to the patients surveyed, and thus, they 
cannot be generalized to other patients. 
Second, we relied exclusively upon self-report 
measures for assessing our constructs and the 
use of self-reporting for data selection, so the 
participants’ answers might be subject to social 
desirability bias. 
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